Cognition Therapeutics Q3 net loss narrows as trials ending lower R&D costs

Cognition Therapeutics

06/11/2025 12:43

Overview

Cognition Therapeutics reports Q3 net loss of $4.9 mln, down from $9.9 mln last year

Company completed $30 mln registered direct offering to fund zervimesine development

Outlook

Cognition aligns with FDA on zervimesine registration path for Alzheimer's

Cognition's $30 mln offering supports zervimesine's next development stage

Result Drivers

R&D EXPENSES - Decrease driven by completion of SHINE and SHIMMER trials

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$4.93 mln
Q3 Income From Operations
-$6.38 mln
Q3 Operating Expenses
$6.38 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Cognition Therapeutics Inc is $3.50, about 51.7% above its November 5 closing price of $1.69

Press Release: ID:nGNX6S89Jj

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)